Pfizer Overview
Valuation check: PFE's P/E ratio is 35.33, above the Healthcare sector average of 26.36.
Get informed when a big investor buys or sells
+ Follow35.33
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for PFE is 35.33. That is above the Healthcare sector average of 26.36. Investors often review this figure alongside Pfizer's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PFE currently prints 35.33 for P/E ratio, while the sector average sits near 26.36. That is roughly 34.0% above the sector mean. Large gaps often invite a closer look at Pfizer's growth, margins, and balance sheet.
A P/E ratio of 35.33 for Pfizer is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with PFE's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting PFE's P/E ratio (35.33), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Pfizer's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
